In this retrospective population-based study of HER2 + aBC, the incidence of cardiac events during or after trastuzumab-based therapy was 7.3%, (n = 167) with heart failure representing the majority of these events (6.9%, n = 158). This evidence concerns the gene ERBB2 and heart failure.